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Abstract
Background: Miltefosine, which is the first oral drug licensed for the treatment of leishmaniasis, was recently
reported to be a promising lead compound for the synthesis of novel antischistosomal derivatives with potent
activity in vivo against different developmental stages of Schistosoma mansoni. In this paper an in vitro study was
carried out to investigate whether it has a biocidal activity against the aquatic stages of Schistosoma mansoni and
its snail intermediate host, Biomphalaria alexandrina , thus being also a molluscicide. Additionally, to see whether
miltefosine can have a broad spectrum antischistosomal activity, a similar in vitro study was carried out on the
adult stage of Schistosoma haematobium, the second major human species, its larval stages and snail intermediate
host, Bulinus truncutes. This was checked by scanning electron microscopy.
Results: Miltefosine proved to have in vitro ovicidal, schistolarvicidal and lethal activity on adult worms of both
Schistosoma species and has considerable molluscicidal activity on their snail hosts. Scanning electron microscopy
revealed several morphological changes on the different stages of the parasite and on the soft body of the snail,
which further strengthens the current evidence of miltefosine’s activity. This is the first report of mollusicidal
activity of miltefosine and its in vitro schistosomicidal activity against S.haematobium.
Conclusions: This study highlights miltefosine not only as a potential promising lead compound for the synthesis
of novel broad spectrum schistosomicidal derivatives, but also for molluscicidals.
Background
Miltefosine (hexadecylphosphocholine) is one of several
alkyllysophospholipid derivatives collectively known as
alkylphosphocholines that were originally developed as
anticancer agents [1]. The biocidal action of miltefosine
against Leishmania species was demonstrated in the
mid 1980s [2,3] and since then, trials for its clinical eva-
luation have led to the licensing of miltefosine for the
oral treatment of leishmaniasis in India, Colombia, and
Germany [4-6]. Miltefosine is also active against a vari-
ety of protozoa, and more and more data have become
available on its activity against other Kinetoplastidae
(Trypanosoma cruzi and T. brucei) [7,8], Trichomonas
vaginalis [9], Entamoeba histolytica [10] and several free
living amoebas [11-13]. Apart from its antiprotozoal
effect, various bioactivities of miltefosine have been
reported; it has a broad spectrum antifungal activity
[14], bactericidal activity against Streptococcus pneumo-
niae and other pathogenic Streptococci [15], and it is
under investigation as a potential therapy against HIV
infection [16]. The mechanism underlying broad range
bioactivities and the target (s) is still unrevealed. Most
recently, miltefosine was reported to have anthelminthic
properties. In a study done in 2011 [17], miltefosine was
found to have schistosomicidal activity and showed
comparative advantage over PZQ in being effective
against in vivo differential developmental stages of Schis-
tosoma mansoni in the mouse model.
Schistosomiasis is one of the most prevalent diseases
in the world, with about 200 million human beings
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any medium, provided the original work is properly cited.infected in 74 countries. It is estimated that 20 million
of them have serious forms of the disease or related dis-
abilities, and that 200,000 people die from the disease
every year [18]. Chemotherapeutic measures have been
the mainstay in the control of this disease [19]. Since
1970, praziquantel (PZQ) has become the drug of choice
against the three major human species of schistosomes,
Schistosoma mansoni (Sambon), Schistosoma hemato-
bium (Bilharz), and Schistosoma japonicum (Katsurada)
[20,21]. It is a relatively safe, orally administered drug
that leads to reduction of the prevalence of schistoso-
miasis [22]. Consequently a targeted as well as mass
drug administration program presently relies heavily on
this drug for the control of schistosome-induced
morbidity.
With only one drug of choice for treatment and the
possibility of development of parasite resistance [23-27],
the present situation is dangerous. Therefore, there is a
real need for discovery of a new drug.
Though chemotherapy is one of the most effective
methods for the control of schistosomiasis [28], there is a
basic need for more selective and efficient molluscicides
for the control of the snail vectors. The control of snails
is an important means in the combat against this disease.
The presently available synthetic molluscicides tend to be
generally biocidal affecting many other animals and/or
plants in the snail habitat [29]. Therefore, there is a need
to search for other molluscicides with strong but specific
activity and less harmful to the environment. As miltefo-
sine, was reported to be a promising lead compound for
the synthesis of novel anti-schistosomal derivatives with
potent activity against in vivo different developmental
stages of S. mansoni [17], this study was carried out to
investigate whether a similar activity can also exist
against its aquatic stages and its snail intermediate host,
Biomphalaria alexandrina, thus being a molluscicide. In
addition, to elucidate whether miltefosine can have a
broad spectrum antischistosomal activity, a similar in
vitro study was carried out on the same stages, the inter-
mediate host, and the adult worm of Schistosoma haema-
tobium the second major human species. Miltefosine
efficacy was evaluated on basis of in vitro bioactivity test-
ing supported by scanning electron microscopy.
Materials and methods
Drug
Miltefosine (Milteforan
®) 2% veterinary oral solution
was kindly supplied by Dr. Paolo Bianciardi, Scientific
Advisor,Virbac, Italy.
Bioactivity testing
In vitro schistosomicidal bioassay
The schistosomicidal in vitro b i o a s s a yu s e dh e r ef o l -
lowed the main procedure previously described by [30]
and [31]. Thus, the schistosome material Schistosoma
mansoni (Sambon) and S. haematobium (Bilharz) was
obtained from the Schistosome Biological Supply Centre
(SBSC), Theodor Bilharz Research Institute (TBRI),
Cairo, Egypt. Mature worms were obtained from ham-
sters (Mesocricetus auratus), percutaneously infected
with 350-400 S. mansoni cercariae per hamster 6-7
weeks earlier, and with S. haematobium cercariae 11-12
weeks earlier. The worms were obtained by perfusion
using citrated saline, and the recovered worms were
washed from blood in small sieves (20 μmm e s h )b y
phosphate buffer. Worms were washed three times with
the culture medium which is used for the assay under a
sterilized laminar flow chamber. The culture medium
used was RPMI 1640 + l-glutamine + 20% fetal calf
serum + antibiotics (300μg streptomycin + 300 IU peni-
cillin + 160 μg gentamycin per ml). The bioassay was
carried out using 24 wells tissue culture plates. A stock
solution 5 mg/ml of the compound was prepared in
DMSO immediately before being used. Three pairs of
worms, males and females equally were used for each
test well in 2 ml medium and 2 replicats were set up for
each species in each case. Exposure of worms to a stan-
dard concentration of 10 μg/ml of miltefosine (25 uM)
was made for 5 days at 37°C ± 0.5°C in 5% CO2 incuba-
tor. A pure medium and a medium containing 0.5% of
DMSO (vehicle) were used as negative controls, while
praziquantel at 10 μg/ml was used as a reference drug.
Worms were examined for their viability using a stereo-
microscope, and those not showing motility for one
minute were considered dead. The mortality rate of
worms was calculated after 5 days exposure. The com-
pound was then retested (secondary screen) using the
same technique by successive descending dilutions of
the solution. The mortality of worms was determined in
each case and the LC50 and LC90 were calculated. The
statistical program SPSS version 7.5 was used for the
calculation.
Larvicidal (ovicidal, miracidicidal and cercaricidal) activity
Eggs, miracidia and cercariae of S. mansoni and S. hae-
matobium were also obtained from SBSC. The eggs
were extracted from the intestines of infected hamsters
(Mescoricetus aurautus). Miracidia were obtained from
cleaned eggs by hatching them in small amounts of
dechlorinated tap water. The cercariae were procured
from experimentally infected B. alexandrina and B.trun-
catus snails at 25°C ± 2°C. The eggs, miracidia and cer-
cariae of both Schistosoma spp. were exposed to the
LC50 of miltefosine determined below on snails for 30
min., 25 min and 20 min respectively. Sinking down of
the miracidia and cercariae with detachment of the tail
in the later case give indication of death of these
organisms.
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The snail material used were Biomphalaria alexandrina
(Ehrenberg) and Bulinus truncatus (Audouin), the vectors
of S. mansoni and S. haematobium in Egypt respectively.
They were also obtained from the colonies maintained in
SBSC. Adult B. alexandrina and B. truncatus snails 4-6
mm in diameter and 2-3 mm shell height respectively
were used for testing the molluscicidal activity of miltefo-
sine. The snails were fed on boiled lettuce leaves, blue
green algae and fish food.
The efficacy of miltefosine against the adult snails was
primarily determined using the standard method of World
Health Organization recommendations [29]. Thus one liter
of solution with a concentration 20 ppm was prepared and
10 snails were added. The snails were maintained in the
solution for 24 h at 25°C + 2°C. After exposure, the snails
were thoroughly washed and transferred to fresh water for
another 24 h for recovery. Two replicas were carried out
and two groups of snails were run in fresh dechlorinated
water under the same experimental conditions as the nega-
tive control. The currently conventional molluscicide
(Niclosamide) was used similarly as positive control. At the
end of recovery period, the snails were examined for viabi-
lity, and the dead snails were counted and recorded to cal-
culate the mortality rate. Miltefosine was then retested by
the same method using descending concentrations for
LC50 and LC90 determination. The statistical program
SPSS package version 7.5 was used for calculation.
Scanning electron microscopy study
Eggs, miracidia, cercariae as well as adult worms of
Schistosoma mansoni, and the soft body of its snail host,
B. alexandrina, exposed to miltefosine, and non exposed
samples that served as controls were fixed in a 10% glu-
taraldehyde and processed for examination by SEM [32].
Ethical approval
All animal studies presented here have been approved
by the local government based on national regulations
for animal experimentation.
Results & discussion
In vitro schistosomicidal activity
Miltefosine showed 100% mortality of worms at 10 μg/ml
after 5 days exposure. It was slightly more effective on
adult worms of S. haematobium than on S. mansoni with
LC50 of 5.1 μg/ml and 5.8 μg/ml for the two spp. respec-
tively. However this effect is still much less than that of
the reference drug (PZQ) which gave LC50 =0 . 2μg/ml
after 5 days under the same condition (Table 1). This dif-
ference in susceptibility of the two species to miltefosine
may be explained by one of the several hypotheses raised
by Eissa et al., 2011 [17] for the possible mechanisms of
action of miltefosine in schistosomiasis. They postulated
that miltefosine may act through acetylcholine esterase
inhibition due to the presence of phosphocholine moiety
in its structure, a mechanism of action which is well
known for the potent schistosomicidal drug, metrifonate,
which was widely used against S.haematobium in the
1990s, and then withdrawn from the market because of
medical, operational and economic criteria [33,34]. It is
well known that S. mansoni and S. haematobium differ in
their sensitivity to this therapeutic anticholinesterase,
metrifonte, that exhibits activity against S. haematobium
singly [35,36]. As Miltefosine was postulated to have
anticholine esterase activity, we hypothesize that this may
act synergistically with other postulated mechanisms
raised for miltefosine by Eissa et al., 2011 [17], thus
explaining the slight difference of susceptibility of the
two species to miltefosine. However, further research is
needed to provide a better understanding of the contri-
bution of this factor in determining the different suscept-
ibility of the two spp. to miltefosine.
In the present study, SEM of adult male S.mansoni
worm exposed in vitro to miltefosine at a concentration of
10 ug/ml (25 uM) showed distortion of the tubercles on
the dorsal tegumental surface (Figure 1A). There was ero-
sion of the tegumental surface (Figure 1B, C) with appear-
ance of subtegumental tissue (Figure 1D). There was also
constriction at the posterior end of the worm (Figure 1E).
The normal dorsal tegumental tubercles from the negative
controls (pure medium controls) are shown in (Figure 1F).
SEM of worms from DMSO controls appeared similar to
those from pure medium controls. SEM of the tegument
of adult S. mansoni worms has been described since the
seventies [37,38]. The present results show that miltefosine
caused disintegration of the tubercles on the dorsal tegu-
mental surface with its sloughing and erosion leading to
exposure of the subtegumental tissue. These findings are
similar but more pronounced than the changes observed
by Eissa et al., 2011 [17] in their in vivo study. These
results are also in accordance with tegumental alteration
induced by mefloquine on adult S. mansoni in both
in vitro and in vivo studies [39].
Ovicidal, miracidicidal and cercaricidal activities
Miltefosine proved to have clear schistolarvicidal effect
on S. mansoni and S. haematobium. Thus eggs did not
Table 1 In vitro schistosomicidal activity of miltefosine
on Schistosoma mansoni and Schistosoma haematobium
adult worms (after 5 days exposure).
Schistosoma spp. Miltefosine Praziquantel
LC50
μg/ml
LC90
μg/ml
LC50
μg/ml
LC90
μg/ml
S.mansoni 5.8 8.2 0.2 0.3
S.haematobium 5.1 7.1 0.2 0.3
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the corresponding snail vector (Table 2). However, the
drug was more effective on S. haematobium than on S.
mansoni. The compound leads to reduction in the
movement of the miracidia and the sinking down of the
cercariae to the bottom of the container with detach-
ment of the tails. This was followed by the death of
both organisms. Thus, this study showed also that milte-
fosine not only possesses the potential of being broad
spectrum antischistosomal compound but also has
schistolarvicidal activity against aquatic stages of both S.
mansoni and S. haematobium. The biocidal activity of
miltefosine was demonstrated against S. mansoni and S.
haematobium eggs, leading to prevention of hatching
when eggs were exposed to the mollusicicdal LC50, half
and quarter this compound concentration. SEM study of
S. mansoni egg showed that normal egg has microspi-
cules like chitinous minute projections densely distribu-
ted all over the surface (Figure 2A& B). On the other
hand, eggs exposed to miltefosine at a concentration
of 3.75 ppm showed patchy loss of these projections
(Figure 2C, D). The remaining ones became oedematous
and swollen (Figure 2E). Previous literature showed that
the egg shell of S. mansoni consists of dense material
with multiple microspicules on its outer surface and
pores through its thickness [40]. Within the shell is the
live miracidium, which releases enzymes and antigens
[41]. The present SEM of S. mansoni eggs after expo-
sure to miltefosine showed destruction and patchy loss
of the microspicules of the egg shell, which may
Figure 1 Scanning electron microscopy (SEM) of adult Schistosoma mansoni: in vitro exposed adult to miltefosine showing: (A) distorted
dorsal tegumental tubercles on the dorsal surface (T) (× 5000), (B) erosion of the tegumental surface (E) (× 3500), (C) higher magnification of (B)
(× 7500), (D) appearance of subtegumental tissue (ST) (× 15000), (E) constriction at the posterior end of the worm (®) (× 350). Unexposed adult
showing: (F) dorsal tegumental tubercle (T) of a normal male worm showing its spines (S) and papillae (P) (× 10000).
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Schistosoma
spp.
Concentration of
Miltefosine
Solution (μg/m l)
Molluscidal LC50
Ovicicdal
Effect
Miracidicidal
Effect
Cercaricidal
Effect
100% mortality after
(minutes)
100% mortality after
(minutes)
100% mortality after
(minutes)
S. mansoni 7.5 5 10 20
3.75 (1/2) 10 15 30
1.85 (1/4) 20 20 40
0.925 (1/8) 30 30 50
S. haematobium 2.6 10 20 30
1.3 (1/2) 20 30 45
0.65 (1/4) 0 40 55
0.33 (1/8) 0 60 60
Figure 2 Scanning electron microscopy (SEM) of Schistosoma mansoni eggs: unexposed eggs showing: (A) oval egg with lateral spine (S)
(× 2000), (B) the surface of the egg showed microspicules like chitinous projections (®) (× 35000). Exposed eggs to miltefosine showing: (C)
patchy loss of the microspicules like chitinous projections (®) (× 2000), (D) higher magnification of (C) (× 15000), (E) swollen and oedematous
chitinous projections (®) (× 35000).
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way inside the eggs. This, in addition to the porous shell
of the egg that allows the drug to reach the metaboli-
cally active miracidium, where it may interfere with its
antigenic substances and enzymes leading to the loss of
their capability of hatching. Hatching of Schistosoma
eggs is the culmulation of multiple biological processes
and severe damage to several of these processes may be
needed to be manifest as a decrease in the release of
miracidia [40]. Further documenting this hypothesis is
the observation of small granuloma size in the liver of
experimentally infected mice with S. mansoni after treat-
ment with miltefosine [17], that was explained by the
authors due to the effect on eggs in situ by miltefosine
which is known to accumulate in the liver after oral
administration, thus diminishing the capacity of the eggs
to induce delayed type hypersensitivity granulomas in
the liver. Impairment of the antigenic products is clearly
important to the host as morbid complications of schis-
tosomiasis are largely related to the granulomatous and
fibrotic responses to egg deposition in the tissues [42].
The present study showed also that miltefosine has
biocidal activity against miracidia and cercariae of both
Schistosoma species. Miltefosine leads to the reduction
in movement of miracidia and sinking of the cercariae
to the bottom of the container, this was followed by the
death of both organisms. SEM studies showed that the
normal unexposed miracidium of S. mansoni is covered
with cilia (Figure 3A, B). The apical papillae showed the
characteristic honey comb pattern of its terebratorium
(Figure 3C). where as, the miracidium exposed to milte-
fosine at a concentration of 3.75 ppm showed distinct
loss of cilia from its surface (Figure 3D) and the pro-
truded apical papillae showed swollen oedematous cor-
rugated areas (Figure 3E, F).
An SEM study of miracidia has been previously car-
ried out by [43] and [44]. SEM of S.mansoni miracidium
exposed to miltefosine showed loss of cilia from its sur-
face, and the protruded apical papilla showed swollen
oedematous corrugated areas. As a result the miraci-
dium loses its ability to swim in water searching for its
snail host. It may also lose its capability to penetrate the
snails, because of the changes in the apical papilla [43].
In the present study, SEM of unexposed cercariae
showed that the cercarial glycocalyx envelops the whole
organism (Figure 4A). The most anterior part of the
head is provided with spiny tegumental folds (Figure
4B). At the body region the surface was irregular show-
ing invagination and infolding of the tegument forming
frequent tubular profiles (Figure 4B). The body is cov-
ered with numerous spines which are posteriorly direc-
ted and are covered with a glycocalyx that obscured
these spines (Figure 4C). The cercarial tail and its furcu-
lae are covered by the glycocalyx similar to that seen on
the body but the tips of the spines were often visible,
larger and sharper than those of the body (Figure 4D).
Cercariae exposed to miltefosine at a concentration of
3.75 ppm showed partial detachment of the body from
the tail (Figure 4E), whereas in other cercariae, the body
appeared completely separated from the tail (Figure 4F).
There was marked loss of the glycocalyx, and thining of
the tegument leading to external protrusion or surface
blebbing (Figure 4E, G, inset), with focal loss of spines
from the tegument (Figure 4H). SEM of S. mansoni cer-
cariae has been described in a number of studies
[45,46]. In the present study, S. mansoni cercariae
exposed to miltefosine at concentration 3.75 ppm
showed different morphological changes. Gross changes
were observed, including loss of tails in about 80% of
cercariae. These observations were consistent with the
report of [47] and [48] which showed that hinokitiol (b-
thujaplicin), a compound for potential skin application
against cercarial penetration leads to loss of cercarial tail
in about 50% of cercariae thus affecting cercarial move-
ment and swimming activity. SEM also revealed loss of
glycocalyx resulting in the thinning of the tegument
causing external protrusion or surface blebbing with
focal loss of spines. These changes are similar to the
changes observed on the cercariae of S.mansoni exposed
to hinokitiol by [48]. Those authors suggested that the
structural changes may account for the inability of hino-
kitiol-treated cercariae to infect the host. Moreover, the
surface blebbing is considered as an indicator for stress
and has been observed in previous SEM studies evaluat-
ing anti-schistosomal drugs [49,39].
Molluscicidal activity
The results of this study showed that miltefosine has a
considerable molluscicidal effect on both B. alexandrina
and B. truncatus snails. B. truncatus is considrably more
susceptible than B. alexandrina,L C 50 for Bulinus was
2.6 ppm vs. 7.5 ppm for Biomphalaria after 24 h at 26°
C. This molluscicidal effect is still much lower than that
of niclosamide which is the conventional synthetic mol-
luscicide commonly used at present, LC50 of niclosa-
mide is 0.2 ppm under the same condition (Table 3).
SEM of the unexposed soft body of B. alexandrina snail
showed that the ventral surface of the foot is covered
with cilia (Figure 5A, B) whereas, the tegumental surface
of the mantle covering the visceral mass is almost
smooth (Figure 5C). B. alexandrina snails exposed to
miltefosine at concentration of 5 ppm showed extensive
damage of the cilia at the foot (Figure 5D). There was
also extensive damage of the tentacles with erosion and
exfoliation especially at its apical part with appearance
of the subtegumental tissue (Figure 5E). The mantle
showed erosion, peeling and exfoliation of its tegumen-
tal surface that resulted in the exposure of the
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reminiscent of the morphological changes observed in
scanning electron microscopy of tumor cells treated
with miltefosine [50] and in adult Schistosoma mansoni
after experimental in vivo treatment with miltefosine
[17].
A review of the literature showed that a number of
studies have been carried out on the effect of several
compounds and plant extracts on miracidia and cercar-
iae as well as medically important snails with various
degrees of success [51-54].
Although, the results of this study demonstrated the
molluscicidal activity of miltefosine, its broad biocide
activity may makes it unsuitable for snail control.
Therefore, this study draws attention to miltefosine as a
promising lead compound for the synthesis of more
potent and selective molluscicidal derivatives.
Conclusions
This study showed that miltefosine has a schistolarvici-
dal activity on the different aquatic stages of S.mansoni
and S.haematobium, and a lethal in vitro effect on adult
worm of both species. In addition, considerable mollus-
cicidal activity was also demonstrated against their snail
hosts. These biocidal activities were supported by SEM
studies which further strengthen current evidence of
miltefosine’s activity. To the best of our knowledge, this
is the first report of mollusicidal activity of miltefosine
Figure 3 Scanning electron microscopy (SEM) of S. mansoni miracidia, unexposed miracidia showing: (A) cilia (C) covering the surface of
the miracidium (®) (× 20000), (B) cilia (C) covering the miracidium (®) and extending from its lateral side (× 10000), (C) the apical papillae of
the miracidium with its characteristic honey comb pattern of its terebratoria (®) (× 20000). Miracidium exposed to miltefosine showing: (D) loss
of cilia from the surface of miracidium (× 20000), (E) protruded apical papillae with swollen oedematous corregated areas (× 10000), (F) higher
magnification of (E) (× 20000).
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Page 7 of 11Figure 4 Scanning electron microscopy (SEM) of Schistosoma mansoni cercariae: normal cercaria showing: (A) cercarial body (B) and tail (T)
with its two furculae (F), covered with glycocalyx (G) (× 1000), (B) tegumental folds (F) at the most anterior part of the head and evident tubular
profiles (P) (× 15000), (C) numerous spines (S) covering the body region which are directed posteriorly and are covered with a glycocalyx that
obscured these spines (× 20000), (D) the cercarial tail with its two furculae covered with glycocalyx (G) identical to that seen on the body but
the tips of the spines (S) were often visible, larger and sharper than those of the body (× 7500). Cercaria exposed to miltefosine showing: (E)
partial detachment of the body from the tail (®) with marked loss of the glycocalyx, thining of the tegument (®) and surface blebbing (×
1000), (F) separated cercarial body (× 2000), (G) surface blebbing of the tegument (B) (× 2000, inset × 15000). (H) focal loss of tegumental
spines (®) (× 20000).
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matobium. Thus, this study highlights miltefosine not
only as a potential promising lead compound for the
synthesis of novel broad spectrum schistosomicidal deri-
vatives but also for molluscicidals.
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Table 3 Molluscicidal activity of miltefosine on
Biomphalaria alexandrina and Bulinus truncatus snails
after 24 hours at 25°C + 2°C
Snail species Miltefosine Niclosamide
LC50
(ppm)
LC90
(ppm)
LC50
(ppm)
LC90
(ppm)
B. alexandrina 7.5 9.9 0.2 0.6
B. truncates 2.6 4.2 0.2 0. 6
Figure 5 Scanning electron microscopy (SEM) of Biomphalaria alexandrina snail (soft part): normal snail showing: (A) densly attached
numerous cilia (C) at the ventral surface of the foot region (× 2000), (B) higher magnification of (A) showing cilia (C) (× 7500), (C) smooth
tegumental surface of the mantle/visceral mass (× 750). Snail exposed to miltefosine showing: (D) extensive damage of the cilia at the foot
region (C) (× 2000), (E) extensive damage of the tentacles with erosion (E) and exfoliation especially at its apical part with appearance of the
subtegumental tissue (× 1000), (F) the mantle showed erosion (E), peeling (P) and exfoliation of its tegumental surface that results in exposure
of the subtegumental tissue (ST) (× 750).
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